With growth in revenue of 11%, or 9% when measured in local currencies, in the
first nine months of the financial year, developments remain satisfactory for
Ambu. Year-to-date revenue was DKK 647.3m against DKK 582.8m last year. The
operating profit - EBIT - for the first nine months of the financial year was
DKK 62.2m, including non-recurring expenses and special items of DKK 13.2m
against DKK 69.1m last year. The EBIT margin was 9.6%, and before non-recurring
expenses and special items 11.6%.
Ambu has achieved significantly higher growth than the estimated general market
growth of 3-5%. In the USA, which is more acutely affected by the financial
crisis than other countries, Ambu saw solid growth of approx. 12% in the local
currency year to date. The health sector is affected by the global crisis, but
Ambu is currently only sensing the economic downturn to a very limited extent.
The outlook for FY 2008/09 (before special items relating to the pending patent
cases) remains of revenue of approx. DKK 850m and an EBIT of approx. DKK 100m.
